Pfizer has reported that an experimental antibody has shown promise in helping cancer patients with cachexia, a condition that causes weight loss. The antibody not only helped patients regain weight compared to a placebo, but also increased their muscle mass and activity levels. This indicates that the weight gain translated into significant benefits for the patients’ overall wellness. Pfizer’s head of discovery and early development, Charlotte Allerton, highlighted the importance of not only the weight gain but also the positive impact on patient wellness. Cachexia is an under-recognized syndrome in advanced cancer patients, and this research could lead to potential new treatments.
Source link
Pfizer drug shows promise in condition that causes weight loss and weakness
